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Toll-like Receptors and Antimicrobial Peptides Expressions of 
Psoriasis: Correlation with Serum Vitamin D Level
To evaluate the association of Toll-like receptors (TLRs), antimicrobial peptides (AMPs) and 
vitamin D receptors (VDRs) in psoriasis, lesional (PP) and perilesional skin (PN) from psoriasis, 
atopic dermatitis (AD) patients and healthy controls (NN) were studied by 
immunohistochemistry. Compared with PN, AD and NN skin, dysregulated expression of 
TLRs, AMPs and VDR was detected in PP skin. Noteworthy, our results showed altered 
correlation between TLR2 and VDR expression in PP and PN skin. Human beta defensin 2 
(HBD2) and cathelicidin (LL-37) expressions in the PP skin were higher in serum vitamin D 
sufficient (VDS) groups than serum vitamin D deficient (VDD) groups. Negative correlation 
was found between TLR2 and VDR expression in the PP skin of VDD groups. However, 
positive correlation was noted in the PP skin of VDS groups. Based on the present results, 
therapies targeting the activity of TLRs, AMPs and vitamin D, including modulation of the 
TLR-VDR pathways, might provide new therapeutic approaches to the psoriasis and other 
inflammatory skin diseases.
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INTRODUCTION
Psoriasis is a chronic relapsing skin disease mediated by ele-
ments of the innate and adaptive immune systems. Psoriatic 
skin is characterized by abnormal keratinocyte differentiation 
and proliferation. Signals derived from immune cells, such as 
proinflammatory cytokines, are able to stimulate keratinocyte 
proliferation, and the keratinocytes themselves may modulate 
immune cells through surface and secretory molecules. These 
molecules consist of toll-like receptors (TLRs), antimicrobial 
peptides (AMPs), and the active metabolite of vitamin D, 
1,25(OH)2D3 (1).
  Although the role of the TLRs in the pathogenesis of psoriasis 
remains to be clarified, TLR expression has been studied with 
conflicting results. Epidermal keratinocytes in normal skin con-
stitutively expressed TLR1, TLR2 and TLR5, while TLR3 and 
TLR4 were barely detectable. TLR1 and TLR2 are expressed in 
entire epidermis, but more highly expressed in the basal kerati-
nocytes. TLR5 is exclusively expressed in the basal cell layer (2). 
In contrast, in lesional psoriatic skin, strong TLR1 staining is 
observed in the keratinocytes of the upper epidermis. TLR2 is 
highly expressed in the keratinocytes of the upper epidermis, 
but not in the basal layer, whereas TLR5 is down-regulated in 
the basal keratinocytes of patients with psoriasis. TLR3 and TLR4 
are weakly expressed in healthy and psoriatic skin (1, 2). 
  AMPs are involved in microbial infection, wound healing, and 
proinflammatory cytokine responses; they have been suggest-
ed to be involved in psoriasis (1). Inflammation, infection or in-
jury may direct keratinocytes to enhance synthesis of AMP in 
the skin (3). Expression of human beta defensin (HBDs), such 
as HBD2 and HBD3, has been reported to be upregulated by 
TNF-α and IFN-γ in normal human keratinocytes (4). In addi-
tion, the HBD2 in keratinocytes can be induced by bacteria and 
vitamin D. However, HBD3 expression is stimulated by TLR2 
interactions with bacterial components (1, 5). Cathelicidin LL-
37, another AMP, is expressed by keratinocytes; its production 
can also be stimulated by vitamin D (6). Expression levels of 
these three AMPs are increased in psoriatic skin compared to 
the skin of patients with lesional atopic dermatitis (4, 7). How-
ever, the correlation of their expression with TLR expression as 
well as vitamin D levels has not been analyzed.
  Vitamin D is produced by keratinocytes and regulates kerati-
nocyte differentiation. The biological effects of 1,25(OH)2D3 are 
mediated through the vitamin D receptor (VDR) (8). The metab-
olite, 1,25(OH)2D3, inhibits keratinocyte proliferation and in-
duces terminal differentiation of the keratinocytes. Vitamin D 
also modulates the immune system in a variety of ways (9-11). 
Although some suggest that serum vitamin D levels in psoriasis 
are inversely related to disease severity, others have shown no 
difference in the serum vitamin D levels between patients with 
psoriasis and in healthy subjects (12).
  In this study, to gain insight into the association of TLRs, AMPs, 
and vitamin D in patients with psoriasis we compared the ex-
pression of TLRs, AMPs, and VDR in the epidermal keratino-Kim SK, et al.  •  Toll-like Receptors, Antimicrobial Peptides and Vitamin D in Psoriasis Patients
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cytes of patients with psoriasis, atopic dermatitis and healthy 
controls. In addition, the correlation of the expression of these 
molecules, serum vitamin D concentrations and psoriasis dis-
ease severity were evaluated. We also compared the expression 
of these molecules between serum vitamin D sufficient (VDS) 
and vitamin D deficient (VDD) patients with psoriasis.
MATERIALS AND METHODS
Subjects
Twelve patients with newly diagnosed psoriasis (9 men and 3 
women) were enrolled from the dermatology department of 
Ajou University Hospital from January to June, 2008 (Table 1). 
The controls consisted of 12 age, gender, and biopsy site match-
ed patients with atopic dermatitis and no other evident derma-
tological disease (average disease duration, 86 months; 5-120 
months), and 12 healthy volunteers. For the comparison be-
tween VDS and VDD patients with psoriasis, we added retro-
spectively, eight more psoriasis patients with decreased serum 
vitamin D levels to the VDD group due to the small number of 
patients in the VDD group. 
Psoriasis disease severity index
Before the biopsy was performed, the psoriasis disease severity 
was evaluated. The clinical severity of psoriasis was graded ac-
cording to the area affected by psoriasis area and severity index 
(PASI) scoring system. The PASI score of all patients was deter-
mined by one dermatologist.
Skin biopsy and immunohistochemical studies
For the patients with psoriasis, four to six-millimeter punch bi-
opsies from the lesional (PP) and perilesional normal-appear-
ing (usually 6 cm or more distant) skin (PN) were collected. The 
biopsies from the PP skin were taken within the lesion, 1 cm 
from the edge of the plaque border. The biopsies from the PN 
skin were taken 2 cm beyond the plaque border. Two to three-
millimeter punch biopsies were taken from the lesional skin of 
patients with atopic dermatitis (AD) and from the normal skin 
of the healthy normal controls (NN). Paraffin-embedded tissue 
sections of 3-µm thickness were processed for light microscopic 
examination. 
  Immunohistochemistry with each primary antibody (Ab) was 
performed using standard techniques (13). The primary anti-
bodies included TLR1 (ebioscience, Inc., San Diego, CA, USA), 
TLR2, TLR4 (Abcam, Inc., Cambridge, UK), HBD2 (R&D sys-
tems Inc., Minneapolis, MN, USA), HBD3 (Orbigen, Inc., San 
Diego, CA, USA), cathelicidin (Abcam, Inc., Cambridge, UK), and 
VDR (Affinity Bioreagents, Inc., Golden, CO, USA). The immu-
nohistochemical findings were analyzed by two dermatologists. 
Image analysis
Image signals were recorded on a personal computer and eval-
uated using Image Pro Plus Version 4.5 (Media Cybernetics Co., 
Silver Spring, MD, USA). The image analysis was performed on 
a representative area of each specimen. For each staining, we 
established a standard for Ab positivity and applied the same 
standards to the PP, PN, AD, and NN samples. The amount of 
positive Ab area was measured under the same magnification 
(×100). The ratio of positive Ab area to the measured epidermal 
area (PA/EA) was calculated for the PP, PN, AD, and NN skin 
samples (14-16). Careful examination was performed by manu-
ally tracing the borders of the epidermis and the rete ridges. The 
epidermal areas that contained hair follicles were excluded from 
the tracings. 
Serum 25-hydroxyvitamin D 
Venous blood samples were taken in the standard method. Se-
rum concentrations of 25(OH)D were assayed with a radioim-
munoassay kit (Dia-Sorin, Stillwater, MN, USA). Following ex-
traction of 25(OH)D using a donkey anti-goat (DAG) precipitat-
ing complex, the treated sample was assayed according to the 
equilibrium RIA procedure. The reference range used for the 
assay was 9.0-37.6 µg/mL. Serum 25(OH)D concentrations of 
<9 µg/mL were considered vitamin D deficient (17, 18).
Statistical analysis
Data were expressed as the mean±standard deviation. To com-
pare the PA/EA of TLRs, AMPs, and VDR, independent t-test was 
used for the PP, PN, AD, and NN skin. Spearman’s rho correla-
tion analysis was performed to determine the correlation among 
the TLRs, AMPs, VDRs, serum 25(OH)D levels and PASI score. 
Differences in the PA/EA of TLRs, AMPs, and VDR between the 
VDD and VDS groups were also analyzed using the indepen-
dent t-test. Correlation between TLR2 and VDR expression in 
the VDD and VDS groups were analyzed using Spearman’s rho 
correlation analysis. A probability of less than 0.05 was consid-
ered statistically significant. The SPSS v11.0 statistics program 
(SPSS, Inc., Chicago, IL, USA) was used for the analysis.
Ethics statement
All subjects provided informed consent to participate in this 
study. This study was approved by the institutional review board 
(IRB number: AJIRB-CRO-07-174) and was conducted in ac-
cordance with the declaration of Helsinki principles.
Table 1. Baseline demographics and characteristics of psoriasis patients, atopic 
dermatitis patients and healthy normal control group
Psoriasis  
(n=12)
Atopic dermatitis 
(n=12)
Normal control 
(n=12)
Age (yr) 33.2±9.6 34.8±11.3 35.5±9.2
Gender
   Male (%)
   Female (%)
9 (66.6)
3 (33.3)
9 (66.6)
3 (33.3)
9 (66.6)
3 (33.3)Kim SK, et al.  •  Toll-like Receptors, Antimicrobial Peptides and Vitamin D in Psoriasis Patients
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RESULTS
Quantitative analysis of expression of TLR1, TLR2, TLR4, 
HBD2, HBD3, LL-37 and VDR in psoriasis lesional and 
perilesional skin, atopic dermatitis lesional skin and 
healthy normal control skin
Expression of TLR1 in the PP skin was higher than in the NN skin 
(P=0.006). However, expression of TLR2 in the PP skin was lower 
than in the NN skin (P=0.012). The TLR4 expression was similar 
in the NN and PP skin samples. The expression level of HBD2 
and LL-37 was elevated in the PP skin samples compared to the 
NN skin samples (P=0.044 and 0.007, respectively). However, 
the percentage of HBD3 positive keratinocytes was significantly 
decreased in the epidermal layers of the PP skin compared to 
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Fig. 1. The immunohistochemical studies of psoriasis lesional skin (PP) and 
peri  lesional normal skin (PN), atopic dermatitis lesional skin (AD), healthy 
normal con  trol skin (NN). (A) Expression of TLR1, TLR2 and TLR4. (B) Exp­
ression of HBD2, HBD3 and LL­37. (C) Expression of VDR (×100, inset: ×400).
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Fig. 2. PA/EA of psoriasis lesional skin (PP) and perilesional 
normal skin (PN), atopic dermatitis lesional skin (AD), healthy 
normal control skin (NN) by quantitative analysis. (A) Expression 
of TLR1, TLR2 and TLR4. (B) Expression of HBD2, HBD3 and 
LL­37. (C) Expression of VDR. 
*P<0.05; 
†P<0.01.
PA/EA, Ab positive area per measured epidermal area.Kim SK, et al.  •  Toll-like Receptors, Antimicrobial Peptides and Vitamin D in Psoriasis Patients
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the NN skin (P=0.001). The VDR expression levels declined from 
the NN skin samples to the AD, PN and PP skin samples result-
ing in a five fold reduction in the PP skin samples compared to 
the NN skin samples (P<0.001) (Figs. 1, 2). 
Correlation of the TLRs, AMPs, and VDR expression, 
serum 25(OH)D concentration and disease severity  
in patients with psoriasis
A positive correlation between the TLR2 and TLR1 expression, 
the PASI score and the TLR4 expression was found in the PP skin 
(Fig. 3A, B; TLR2 to TLR1, r=0.493, P=0.001 and PASI score to 
TLR4, r=0.278, P=0.041). Noteworthy, a significant negative cor-
relation was found between TLR2 and VDR expression in the 
PP skin (Fig. 3C; TLR2 to VDR, r=0.390, P=0.045); while a posi-
tive correlation was noted in the PN skin (Fig. 3D; TLR2 to VDR, 
r=0.439, P=0.019). However, there was no significant correlation 
between serum vitamin D levels and the TLR and AMP expres-
sion in the patients with psoriasis.
Different expression and correlation of TLRs, AMPs and 
VDR in psoriasis lesional skin in the serum vitamin D 
deficient group compared to the serum vitamin D sufficient 
group
Using a cut-point of 9 µg/mL, (17, 18) we divided the patients 
with psoriasis into two subgroups; serum vitamin D deficient 
(VDD) group (n=2) and serum vitamin D sufficient (VDS) group 
(n=10). None of the patients with critically low vitamin D levels 
had abnormal serum calcium or inorganic phosphate levels. In 
this preliminary study, HBD2, LL-37 and VDR expression had a 
tendency to be downregulated in the serum VDD group com-
pared to the VDS group. Although the VDD group was a small 
sample, the HBD2 expression was significantly downregulated 
in this group (P=0.049) (data not shown).
  Because the sample size of the VDD group was small, we re-
cruited additional eight patients that had decreased serum vita-
min D levels into the VDD group retrospectively. As described 
in the above preliminary data, HBD2, LL-37 and VDR had a ten-
dency to be downregulated in the VDD group; therefore, addi-
Fig. 3. Correlation between TLRs, AMPs and VDR expressions and PASI score in skin sample of psoriasis. (A) The expression of TLR2 shows a positive correlation with the 
expression of TLR1 in psoriasis lesional skin (r=0.493, P=0.001). (B) The PASI score shows a positive correlation with the expression of TLR4 in psoriasis lesional skin (r=0.278, 
P=0.041). (C) The expression of TLR2 showed a negative correlation with the expression of VDR in psoriasis lesional skin (r=0.390, P=0.045). (D) The expression of TLR2 
shows a positive correlation with the expression of VDR in normal skin of psoriasis (r=0.439, P=0.019). 
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tional experiments were performed on the level of three anti-
bodies. The final comparison of these molecules between the 
VDD (n=10) and VDS groups (n=10) is shown in Fig. 4A. HBD2 
and LL-37 expression was significantly downregulated in the 
VDD group compared to the VDS group (Fig. 4A).
  In Fig. 3C, we showed significant negative correlation between 
TLR2 and VDR expression in the PP skin. In the comparison 
study between the VDD (n=10) and VDS groups (n=10), although 
not significant, negative correlation was also found between 
TLR2 and VDR expression in the PP skin of VDD groups (Fig. 4B; 
r=0.272, P=0.174). However, significant positive correlation was 
noted in the PP skin of VDS groups (Fig. 4C; r=0.146, P=0.048).
DISCUSSION
In this study the epidermal expression levels of TLRs, AMPs, and 
VDR were examined in psoriatic skin samples. In addition, the 
correlation of the molecular expression of these compounds with 
serum vitamin D levels as well as with disease severity was ana-
lyzed. Unlike previous studies which evaluated TLR expression 
or AMP expression using a three to four point scale grading sys-
tem, we analyzed the molecular expression levels by measuring 
the area stained by the relevant antibodies.
  TLR2 expression showed an inverse relationship with VDR 
expression in the PP skin, but a positive correlation with the PN 
skin. A previous report also indicated a positive correlation be-
tween TLR2 and VDR in human macrophages of healthy donors 
(11, 19). They reported that TLR2 activation of normal human 
macrophages up-regulated expression of the vitamin D recep-
tor and the vitamin D-1-hydroxylase genes. This altered corre-
lation between TLR2 and VDR expression in the PP skin, might 
be associated with the development of psoriatic lesions. Liu et 
al. (20) reported that adequate levels of serum vitamin D were 
required for the induction of host-defense mechanisms via TLR2. 
Therefore this altered correlation between TLR2 and VDR could 
be due to a feedback mechanism to regulate further inflamma-
tion in psoriasis. Moreover, both TLR and VDR have recently 
been shown to be crucial in AMP expression of normal human 
monocytes (21). The decreased level of TLR2 and VDR expres-
sion in PP skin in this study also could be caused by a feedback 
mechanism to make inflammation in psoriasis. In this regard, 
the modulation of the TLR-VDR pathways might provide useful 
information for the development of new treatments.
  A weak correlation was found between the expression levels 
of TLR4 and disease severity of the patients with psoriasis. In 
patients with spondyloarthropathy, a chronic inflammatory 
Fig. 4. Different expression and correlation of TLRs, AMPs and VDR in psoriasis lesional skin in the serum vitamin D deficient (VDD) group compared to the serum vitamin D 
sufficient (VDS) group. (A) HBD2 and LL­37 expression are significantly downregulated in the VDD group compared to the VDS group. (B, C) Negative correlation is found between 
TLR2 and VDR expression in the VDD groups (B; r=0.272, P=0.174), however, significant positive correlation is noted in the VDS groups (C; r=0.146, P=0.048). 
*P=0.041; 
†P=0.000. PA/EA, Ab positive area per measured epidermal area.
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joint disease, down-modulation of the increased expression of 
TLR4 was found in peripheral monocytes and synovial fluid af-
ter tumor necrosis factor alpha blockade treatment (22). Based 
on previous reports and the results of this study, TLR4 might be 
associated with disease severity in chronic inflammatory dis-
eases. However, because of low correlation coefficient (r=0.28), 
further study is needed to determine the biological relevance of 
the relationship between TLR4 and PASI score. 
  Expression of TLR1 in the PP skin was higher than in the NN 
skin. However, expression of TLR2 in the PP skin was lower than 
in the NN skin. The TLR4 expression was similar in the PP and 
NN skin samples. Consistent with our findings, Seung et al. (23) 
also reported that expression of TLR2 in psoriatic lesional skin 
samples was lower than in normal skin samples, and TLR4 ex-
pression showed no difference in comparisons between normal 
and psoriatic lesional skin samples. According to Wu et al. (24), 
incubated keratinocytes with mouse anti-K16 monoclonal an-
tibodies showed increased TLR2 protein expression, but with-
out change in the TLR4 protein expression. They suggested that 
anti-K16 autoantibodies promoted protein expression of TLR2 
rather than TLR4 expression. Therefore, the modulation of TLR2 
by anti-K16 autoantibodies, rather than TLR4, may be related 
to the chronic inflammation associated with psoriasis. Based 
on these findings and our results, TLR2 and TLR4 appeared to 
play different roles in the development of psoriatic lesions. 
  Consistent with previous reports (1, 25), the expression levels 
of HBD2 and LL-37 were elevated in the PP skin compared to 
NN, AD and PN skin samples. However, HBD3 expression levels 
in the PP skin were lower than in other skin samples. de Jongh 
et al. (25) also reported that expression level of HBD3 was de-
creased in PP skin, as compared to AD and NN skin. According 
to a recent report, HBD3 significantly attenuated the interleu-
kin-6, IL-1, GM-CSF, and TNF-α responses induced by bacteria 
in human myeloid dendritic cells (26). It is possible that the ac-
tivity of HBD3, as an attenuator of pro-inflammatory cytokine 
responses to microbial antigens, might be associated the patho-
genesis of psoriasis. 
  In contrast to the psoriatic skin, AD skin has been shown to 
have decreased levels of AMP expression (4, 7). In contrast to 
the decreased expression of HBD2, HBD3 expression was in-
creased in the AD skin compared to the PP skin, and the LL-37 
expression was increased in the AD skin than NN skin, in this 
study. The disease duration of AD might be a possible cause of 
increased expression levels of HBD3 and LL-37. The immune 
responses in AD were Th2-mediated while those in psoriasis 
were Th1-mediated (4). However, in the chronic phase of AD, 
the immune responses showed Th1-dominant features rather 
than Th2-mediated features. In this study, we performed skin 
biopsies on those in chronic phase of AD, not in the acute exac-
erbation phase (average disease duration, 86 months; 5-120 
months). This might explain the limited difference between the 
AD skin and the PP skin. Therefore, if skin samples from acute 
AD patients can be taken, the results may be different from pres-
ent study.
  VDR expression levels declined in the order of NN, AD, PN 
and PP skin samples resulting in five fold reductions in the PP 
skin compared to the NN skin. These results differed from those 
of Milde et al. (27), who reported on VDR expression in eight 
patients with psoriasis and 10 normal volunteers. They showed 
increased expression of VDR in the psoriatic lesional skin. How-
ever, they did not evaluate the serum vitamin D levels of patients 
(27). VDR has been shown to be upregulated by 1,25-(OH)2D3 
in human keratinocytes (28). Although it was not significant, a 
decreased expression of VDR was detected in the decreased se-
rum vitamin D group in our study. Therefore, this might account 
for the different expression levels of VDR in the patients with 
psoriasis in the present study compared to the levels reported 
in the previous study.
  Expression of HBD2 as well as LL-37 in the PP skin was high-
er in serum vitamin D sufficient patients than serum vitamin D 
deficient patients. Previous reports have suggested that AMP 
expression in epidermal keratinocytes was inducible by high 
calcium concentrations, retinoic acid and 1,25(OH)2D3 (3, 11, 
29). The vitamin D activation step occurred in monocytes and 
keratinocytes by CYP27B1 and was under the control of inflam-
matory stimuli combined with TLR2 (3, 6, 11). Liu et al. (21) also 
demonstrated that HBD2 and LL-37 could be upregulated by 
vitamin D since they had vitamin D response elements in their 
promoter region. Therefore, TLR activation upregulates the ex-
pression of VDR or vitamin D-1-hydroxylase genes, leading to 
the induction of the AMP (3, 11, 30).
  As we mentioned before, significant negative correlation be-
tween TLR2 and VDR expression was noted in the PP skin (Fig. 
3C). In the comparison between the VDD and VDS groups, neg-
ative correlation was also found between TLR2 and VDR expres-
sion in the VDD groups (not significant), while significant posi-
tive correlation was noted in the VDS groups. This altered corre-
lation between TLR2 and VDR expression in the VDD and VDS 
group, might be associated with the role of vitamin D in the de-
velopment of psoriatic lesions.
  In conclusion, dysregulated expression of TLRs, AMPs, and 
VDR was detected in psoriatic skin. Our results showed altered 
correlation between TLR2 and VDR expression in psoriatic le-
sional and non-lesional skin. Our data also showed a correlation 
of the expression levels of HBD2 and LL-37 with serum vitamin 
D levels. Negative correlation was found between TLR2 and VDR 
expression in the PP skin of VDD groups. However, positive cor-
relation is noted in the PP skin of VDS groups. Based on the pres-
ent results, therapies targeting the activity of TLRs, AMPs and 
vitamin D, including modulation of the TLR-VDR pathways, 
might provide new approaches to the management of psoriasis 
and other inflammatory skin diseases. For example, patients Kim SK, et al.  •  Toll-like Receptors, Antimicrobial Peptides and Vitamin D in Psoriasis Patients
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with psoriasis could be divided into VDD and VDS groups and 
treated differently. More well designed studies are needed to 
clarify whether systemic vitamin D supplement can alter the 
disease severity or TLRs and AMPs expressions of psoriasis.
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